The following criteria is provided for health care professionals.

Inclusion Criteria:

• Histologically or cytologically confirmed multiple myeloma
• Prior treatment with or intolerance to proteasome inhibitor and immunomodulator
• Bone marrow biopsy within 28 days of study drug infusion demonstrating at least 5% plasma cell involvement
• Progressive disease defined by any of following:
  • 25% increase in serum M-protein from lowest response value during (or after) last therapy and/or absolute increase in serum M-protein of > 0.5 g/dL;
  • 25% increase in urine M-protein from lowest response value during (or after) last therapy and/or absolute increase in urine M-protein of > 200 mg/24h;
  • 25% increase in bone marrow plasma cell percentage from lowest response value during (or after) last therapy - absolute bone marrow plasma cell percentage must be > 10% unless prior complete response when absolute bone marrow plasma cell percentage must be > 5%;
  • new onset hypercalcemia > 11.5 mg/dL
• Measurable disease defined by any of following:
  • Serum M-protein > 1 g/dL;
  • Urine M-protein > 200 mg/24h;
  • Serum free light chain (FLC) assay: involved FLC level > 10 mg/dL provided serum FLC ratio is abnormal
• Eastern Cooperative Oncology Group performance status of 0 to 2
• Life expectancy of at least 6 months
• Have initiative and means to be compliant with protocol and within geographical proximity to make required study visits as judged by Investigator
• Subject or legal representative has ability to read, understand and provide written informed consent for study related procedures
• Women of childbearing potential must have negative pregnancy test within 24 hours of enrollment
• Women of childbearing potential and men who are able to father a child, must agree to use an effective contraception method during study and for 12 months following study drug administration

Exclusion Criteria:

• Grade 2 or greater toxicities due to previous therapies, subject to laboratory abnormalities listed below. Stable, tolerable Grade 2 adverse events may be allowed at discretion of Investigator
• Prior external beam radiation therapy resulting in greater than 20% total bone marrow receiving greater than 20 Gy
• Prior radioisotope therapy
• Prior total body or hemi-body irradiation
• More than one previous, alkylator-based chemotherapy regimen. Transplantation is considered one alkylator-based chemotherapy regimen. Immunomodulators and proteasome inhibitors are not considered alkylator-based chemotherapy regimens
• Subject has received severely marrow toxic drugs
• Extradural tumor in contact with the spinal cord or tumor located where swelling in response to therapy may impinge upon spinal cord
• Subject has any of following laboratory abnormalities:
  • Platelets < 125,000/L;
  • WBC < 3000/L;
  • ANC < 1500/L;
  • Hemoglobin < 8 g/dL;
  • Estimated glomerular filtration rate < 30 mL/min/1.73 m2;
  • ALT > 3 x ULN ;
  • Bilirubin > 1.5 x ULN
• Chronic immunosuppressive and/or full-dose anticoagulant therapy
• Anti-platelet therapy, except low-dose aspirin for cardioprotection
• PTT > ULN
• INR > ULN
• Radiation therapy, chemotherapy, immunotherapy, investigational therapy or corticosteroid use within 4 weeks of or after eligibility-defining bone marrow biopsy. Bisphosphonates and denosumab are permitted if subject has been receiving for at least 90 days
• History of hypersensitivity to iodine
• Any other concomitant serious illness or organ system dysfunction in opinion of Investigator would either compromise subject safety or interfere with test drug safety evaluation
• Major surgery within 6 weeks of enrollment
• Known history of HIV, hepatitis C or hepatitis B infection
• Pregnancy or breast-feeding